Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Concentric Medical's modified neurovascular retriever:

This article was originally published in Clinica

Executive Summary

The Merci L6 Retriever, a device intended to restore blood flow in the neurovasculature by removing thrombi in patients experiencing ischaemic stroke, has received 510(k) clearance in the US. The product, developed by Concentric Medical, of Mountain View, California, is indicated for use in patients who are ineligible for, or unresponsive to, treatment with intravenous tissue plasminogen activator - clot-dissolving therapy. It may also be used in the retrieval of foreign bodies misplaced during interventional radiological procedures in the neurovasculature or the peripheral or coronary vasculature. The Merci L6 Retriever is a shaped Nitinol wire which can be delivered using standard catheterisation techniques, whereby a small puncture in the groin is used to introduce the retriever into an artery leading to the brain. Upon reaching the targeted area, the Merci retriever is deployed and returns to its original shape. The device incorporates a 2.7mm cylindrical helix with attached filaments; these provide an additional mechanism for securing the clot during retrieval.

You may also be interested in...

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Pipeline Watch: Enhertu, Velexbru, Viltepso Approvals

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts